Skip to main content

Table 4 Reduction in waist and hip circumference in Meratrim and placebo groups over 16 week study period

From: Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects

Parameter Reduction Weeks Placebo Meratrim Net reductiona,b P value
(n = 28) (n = 29)
Waist size (cm) 2 1.07 ± 0.34 1.45 ± 0.25 0.38 (0.4 %) 0.339
4 2.18 ± 20.39 3.38 ± 0.37 1.20 (1.2 %) 0.016*
8 2.82 ± 0.53 5.14 ± 0.49 2.32 (2.3 %) 0.001*
12 3.29 ± 0.58 6.83 ± 0.58 3.54 (3.5 %) <0.001*
16 3.71 ± 0.70 9.97 ± 0.73 6.26 (6.2 %) <0.001*
Hip size (cm) 2 1.04 ± 0.27 1.62 ± 0.26 0.58 (0.5 %) 0.109
4 2.21 ± 0.37 3.14 ± 20.41 0.93 (0.9 %) 0.035*
8 3.61 ± 0.55 4.45 ± 20.51 0.84 (0.8 %) 0.112
12 4.32 ± 0.58 6.55 ± 0.63 2.23 (2.1 %) 0.002*
16 5.11 ± 0.69 10.38 ± 0.85 5.27 (4.9 %) <0.0001*
  1. Values represent mean ± SE
  2. *Significant difference between Meratrim and placebo group mean values calculated using ANCOVA with baseline as covariate
  3. aNet reduction = Meratrim minus placebo
  4. bNumbers in parenthesis represents the % net reduction from baseline for Meratrim group